-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DMT-310 in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DMT-310 in Psoriasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DMT-310 in Psoriasis Drug Details: DMT-310 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DMT-310 in Acne Vulgaris
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DMT-310 in Acne Vulgaris report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DMT-310 in Acne Vulgaris Drug Details: DMT-310 is under development for the...
-
Product Insights
Sudoriferous (Sweat) Gland Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Sudoriferous (Sweat) Gland Disorders - Drugs In Development, 2023’, provides an overview of the Sudoriferous (Sweat) Gland Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sudoriferous (Sweat) Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Axillary Hyperhidrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Axillary Hyperhidrosis - Drugs In Development, 2023’, provides an overview of the Axillary Hyperhidrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DMT-310 in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DMT-310 in Psoriasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DMT-310 in Psoriasis Drug Details:DMT-310 is under development for the treatment of acne vulgaris,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGBA-445 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BGBA-445 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BGBA-445 in Non-Small Cell Lung Cancer Drug Details: BGBA-445...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Docetaxel in Hemolysis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Docetaxel in HemolysisDrug Details:Docetaxel is an antineoplastic agent and anti-mitotic agent. It is formulated as injectable...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DMT-410
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry DMT-410 Drug Details DMT-410 is under development for the treatment of primary axillary hyperhidrosis...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DMT-310
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry DMT-310 Drug Details DMT-310 is under development for the treatment of acne vulgaris, psoriasis...